|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||605.624 g·mol−1|
|3D model (JSmol)|
Tezosentan is a non-selective ETA and ETB receptor antagonist. It acts as a vasodilator and was designed as a therapy for patients with acute heart failure. Recent studies have shown however, that tezosentan does not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events.
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|